1,559 results on '"Krucoff, Mitchell"'
Search Results
2. Abstract 4146824: Performance of Clinician-Assigned SCAI Shock Staging in the AHA Cardiogenic Shock Registry
3. Abstract 4144852: Contemporary Practice Patterns of Vasoactive Agents in Cardiogenic Shock: An Analysis of the AHA Cardiogenic Shock Registry
4. ACTION-ARC Pediatric and Adult Congenital Heart Disease Ventricular Assist Device Adverse Event Definitions-2023
5. Conversations in cardiology: Late career transitions—Retool, retire, refocus
6. One-Month Versus Three-Month Dual-Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease
7. Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial
8. 1- Versus 3-Month DAPT in Older Patients at a High Bleeding Risk Undergoing PCI: Insights from the XIENCE Short DAPT Global Program
9. Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
10. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
11. 1- or 3-Month DAPT in Patients With HBR With or Without Oral Anticoagulant Therapy After PCI
12. Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT
13. Minimum Core Data Elements for Transcatheter Mitral Therapies: Scientific Statement by PASSION CV, HVC, and TVTR
14. Sex-stratified differences in early antithrombotic treatment response in patients presenting with ST-segment elevation myocardial infarction
15. Position Statement on Vascular Access Safety for Percutaneous Devices in AMI Complicated by Cardiogenic Shock
16. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index
17. Randomized evaluation of vessel preparation with orbital atherectomy prior to drug-eluting stent implantation in severely calcified coronary artery lesions: Design and rationale of the ECLIPSE trial
18. Quantifying patients' preferences on tradeoffs between mortality risk and reduced need for target vessel revascularization for claudication.
19. Minimum Core Data Elements for Evaluation of TAVR: A Scientific Statement by PASSION CV, HVC, and TVT Registry
20. Japan-USA Orbital Atherectomy for Calcific Coronary Lesions: COAST Study, Harmonization by Doing Proof-of-Concept
21. Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium
22. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial
23. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy
24. One- Versus Three-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients With Chronic Kidney Disease
25. 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation
26. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI
27. Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction
28. Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program
29. Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies
30. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium
31. Cardiac safety research consortium “shock II” think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock
32. COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial
33. Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank
34. Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era
35. Prehospital crushed versus integral prasugrel loading dose in STEMI patients with a large myocardial area
36. Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study
37. Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock
38. Methodological and Regulatory Considerations for Updated Guidance on the Pressor Effects of Drugs
39. Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease Consensus Definitions From Peripheral Academic Research Consortium (PARC)
40. Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials
41. Opportunities for enhancing the care of older patients with ST-elevation myocardial infarction presenting for primary percutaneous coronary intervention: Rationale and design of the SAFE-STEMI for Seniors trial
42. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry
43. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes
44. Definitions of adverse events associated with extracorporeal membrane oxygenation in children: results of an international Delphi process from the ECMO-CENTRAL ARC
45. Clinical outcomes with thin versus thick strut polymer-free biolimus-coated stents at 3 years.
46. The East–West late lumen loss study: Comparison of angiographic late lumen loss between Eastern and Western drug-eluting stent study cohorts
47. Bursts of reperfusion arrhythmias occur independently of area at risk size and are the first marker of reperfusion injury
48. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry)
49. The Second Annual Think Tank on Prevention of Sudden Cardiac Death in the Young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium
50. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.